Active Digestion, Kidneys & Other Organs Cancer
Ultrasensitive Luminescence-based Yeast Sensors for Specific Early Cancer Sensing
Summary
Original abstract (not yet simplified)ULYSSES is a pioneering project aimed at developing a non-invasive, portable, and user-friendly biosensor for the early detection of breast and prostate cancers through urine analysis. Its core vision is to identify cancer-related volatile organic compounds (VOCs) and develop a biotechnological device for their detection in urine. The innovation lies in mimicking the extraordinary olfactory system of the nematode Caenorhabditis...
View original technical description
ULYSSES is a pioneering project aimed at developing a non-invasive, portable, and user-friendly biosensor for the early detection of breast and prostate cancers through urine analysis. Its core vision is to identify cancer-related volatile organic compounds (VOCs) and develop a biotechnological device for their detection in urine. The innovation lies in mimicking the extraordinary olfactory system of the nematode Caenorhabditis elegans, which can distinguish cancerous from healthy urine with over 90% accuracy. This ability is mediated by a large repertoire of olfactory receptors (ORs) expressed on specialized sensory neurons. ULYSSES replicates this sensing capacity in a synthetic biology framework by introducing selected C. elegans ORs into engineered yeast (Saccharomyces cerevisiae). These ORs are functionally coupled to a bioluminescence resonance energy transfer (BRET)-based biosensing construct. Upon binding cancer-associated VOCs, conformational changes in the ORs trigger measurable BRET signal shifts, serving as indicators of cancer-specific profiles with nanomolar sensitivity. In parallel, urine VOCs will be analysed via gas chromatography–mass spectrometry (GC-MS). Machine learning will be applied to the spectral data to identify key compounds that differentiate cancer from healthy samples and link them to specific OR activation profiles. Engineered yeast biosensors, each with a distinct OR-BRET construct, will be arrayed on a disposable device. Upon urine exposure, BRET signal changes will be recorded and interpreted via an AI algorithm trained on activation heatmaps. This enables the identification of cancer-related patterns with high sensitivity and specificity. Feasibility is ensured by the convergence of expertise within a strongly interdisciplinary consortium. ULYSSES lays the foundation for a versatile diagnostic platform with broad applications in health monitoring and personalized medicine, with strong potential for societal and healthcare impact.
Related Research
Grants with similar aims, by meaning.
Senescence-detecting, urine-based nanobiosensor for early detection of lung cancer
Integrated microfluidic platform with MEMS cantilever for the early detection of prostate cancer using dry mass sensing
Portable electrochemical assay system for on-chip quantitative estimation of bladder cancer biomarkers in real samples
Electrochemical ELISA systems for the rapid, low cost and point of need analysis of clinical samples
A multi-cancer screening platform for fast and accurate early stage cancer detection from urine samples
Original classification
HORIZONPlain English summaries and category classifications on this site are generated by AI and may not perfectly reflect the original research. Is something wrong? Let us know